Abstract 1600P
Background
Lenvatinib and pembrolizumab has demonstrated preclinical synergy in small cell/neuroendocrine cancer cell lines and clinical tolerability is noted A multicenter phase II trial of the combination in NEPC was conducted.
Methods
Eligible patients had histologically proven prostate cancer with radiologic evidence of metastases and either: A) Small-cell or NEPC B) positive staining for chromogranin and synaptophysin C) visceral metastases and a PSA< 5 ng/dL.D) Serum chromogranin A level = 5× upper limit of normal (ULN) and/or serum neuron specific enolase (NSE) = 2× ULN. E) RB1 deletions or mutations F) Trans-differentiated or poorly-differentiated carcinoma. 2 prior chemotherapy regimens were allowed. Performance status of 0-1 and normal marrow, renal and liver function were required. Primary endpoint was 6- month radiologic progression-free survival (rPFS). Stud therapy was Lenvatinib 20 mg orally daily and intravenous pembrolizumab 200 mg every 21 days. Sample size was 27 for first stage and if 3 patients were progression free at 6 months then total accrual was 40 evaluable patients.
Results
33 patients enrolled; median age was 71 years (range- 37-83 years), 3 (10%) black patients and 3 (10%) of Hispanic ethnicity. 13/22 (59%) had Gleason ≥ 8, 31 (94%) patients had small cell/NEPC, 1 patient qualified based on serum NE markers, 1 had transdifferentiated histology. RB loss was noted in 3 of 11 patients. 12/31 (39%) patients had liver metastases and 30 (91%) had measurable disease. 31 (94%) patients received prior chemotherapy and 23 (70%) received prior platinum. No treatment related deaths were noted. Grade 4 toxicities of lipase elevation and urinary obstruction were noted in 1 patient each. Grade 3 toxicities of hypertension, diarrhea, fatigue and proteinuria occurred in 6, 2, 5 and 3 patients respectively. 21 pts are response evaluable to date. 3 (14%) had partial response. 7 (33%) had stable disease. Five patients remain progression free at 6 months. The primary endpoint of first stage was met. Accrual to second stage is ongoing. PFS and OS will be reported.
Conclusions
The combination of lenvatinib and pembrolizumab demonstrated tolerability and promising efficacy in a pretreated patient population with NEPC.
Clinical trial identification
NCT04848337.
Editorial acknowledgement
Legal entity responsible for the study
Hoosier Cancer Research Network.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA provided drug and financial support.
Disclosure
U.N. Vaishampayan: Financial Interests, Personal, Advisory Board, consultant: BMS; Financial Interests, Personal, Advisory Board: Bayer, Gilead, Pfizer, Merck, Exelixis, Novartis; Financial Interests, Institutional, Research Grant, Investigator initiated trial supported by Merck: Merck; Non-Financial Interests, Member of Board of Directors: Michigan Society of Hematology/Oncology. D. Kilari: Financial Interests, Personal, Invited Speaker: Janssen, Pfizer, Aveo oncology, Seagen, MJH - life sciences, Binayatra foundation; Financial Interests, Personal, Advisory Board: Exelixis, Eisai; Financial Interests, Institutional, Coordinating PI: Exelixis, Genentech. T.B. Dorff: Financial Interests, Personal, Advisory Board: AstraZeneca, Janssen, Sanofi, Bayer. A.O. Sokolova: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: Lantheus; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca. Z. Reichert: Financial Interests, Personal, Advisory Board: Huff Powell Bailey, AstraZeneca; Financial Interests, Institutional, Coordinating PI: AstraZeneca, Celgene. J. Alumkal: Financial Interests, Personal, Advisory Board: Fibrogen; Financial Interests, Institutional, Funding: Pfizer, Beactica, Zenith; Financial Interests, Personal and Institutional, Advisory Role, Research award: Astellas; Financial Interests, Personal, Advisory Role: Bristol-Myers-Squibb. All other authors have declared no conflicts of interest.
Resources from the same session
1481P - A case-control study of drug-eluting microspheres and blank microspheres in bronchial artery embolization for hemoptysis in non-small cell lung cancer
Presenter: Tongguo Si
Session: Poster session 10
1482P - Percutaneous transhepatic biliary drainage (PTBD) for palliation of jaundice in patients of unresectable/disseminated carcinoma gall bladder with hilar block: Is it a worthwhile enterprise?
Presenter: Saurabh Galodha
Session: Poster session 10
1484P - Inflammatory patterns of ascites in patients with solid tumors
Presenter: Julia Berger
Session: Poster session 10
1485P - Mitigating symptom clusters of patients with metastatic cancer through a remote physical exercise program (EXIO)
Presenter: Paulo Bergerot
Session: Poster session 10
1486P - A personalized rehabilitation pilot program for improving QOL of unresectable metastatic lung cancer patients
Presenter: Shani Shilo
Session: Poster session 10
1487P - Telemonitoring system effectiveness for alleviating cancer pain in patients with advanced cancer
Presenter: Shiori Yoshida
Session: Poster session 10
1488P - Use of mobile app “SUPPORT+” to enhance community palliative care in advanced cancer patients: A feasibility study
Presenter: Wendy Chan
Session: Poster session 10
1489P - Factors influencing adherence to electronic patient-reported outcomes in palliative cancer care
Presenter: Sarah Gomes
Session: Poster session 10
1490P - Health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain: A cross-sectional analytical study
Presenter: Herald Mapa
Session: Poster session 10
Resources:
Abstract